US FDA To Exercise ‘Maximum Regulatory Flexibility’ For COVID-19 Plasma-Derived Therapeutics

 
• By Sue Sutter
Coronavirus 2019-nCoV Blood Sample. Corona virus outbreaking. Epidemic virus Respiratory Syndrome. China
Industry is seeking plasma donations from individuals who have recovered from COVID-19. • Source: Shutterstock

More from Clinical Trials

More from R&D